Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.

Biotechnology

Abcuro

Alex Martin

Daniel Mansuri

Kristin Lurk

Ricky Motschwiller

Raquel Orozco

Donna Byrne

Terry Chaney

Mike Gress

Karen Tubridy

Garry Weems

Hugo Lemessurier

Dave Borbas

Janaki Subramanyam

Dulce Soler-Ferran

LaDonna Hoffer

H. Jeffrey Wilkins, MD

The executive team at Abcuro has experience in a variety of medical fields. The Chief Medical Officer has worked at Cerecor Inc, Zyla Life Sciences, Onspira Therapeutics, Inc., and Lycera. The team is also educated, with the Chief Medical Officer holding a degree from Temple University - Lewis Katz School of Medicine and another team member holding a degree from Bucknell University.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Abcuro

Leadership Team

Board of Directors